Refine by
Clinical Phase Articles & Analysis
431 news found
To drive rapid adoption, Hemostemix is executing a “boots on the ground” strategy, led by Thomas Smeenk, CEO, and Croom Lawrence, CCO, who are meeting directly with clinicians, clinic owners, and former Phase II clinical trial investigators, across the state. ...
As of the latest research, several experimental gene therapies for glaucoma are in various stages of development, from preclinical studies to early-phase clinical trials. As an innovative ophthalmic disease research company with a wide range of services in basic research, drug development, and preclinical studies, Ace Therapeutics has expanded its portfolio to ...
The research is a retrospective, multimodal analysis of the POSEIDON Phase 3 clinical trial (NCT03164616). This trial originally demonstrated that the combination of tremelimumab, durvalumab, and chemotherapy significantly increases progression-free survival (PFS) and overall survival (OS) versus chemotherapy in patients with metastatic NSCLC, which lead to ...
Additionally, Semaglutide has been shown to delay gastric emptying, leading to a prolonged sense of fullness and reduced appetite, ultimately contributing to significant weight loss in clinical trials. The efficacy of Semaglutide has been extensively studied in numerous phase 3 clinical trials, with consistently impressive results. ...
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders made the NASDAQ Top ten percentage gainers today on news. ...
At present, we have completed approximately 60% of the enrollment of our randomized Phase 2 clinical trial that builds upon our successful Phase 1 trial. Our Phase 2 trial will compare outcomes of babies treated with the standard of care (SOC) plus Lomecel-BTM vs. the SOC alone. ...
Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids Registrational phase 3 clinical trials of cebranopadol in moderate to severe acute pain are on track to initiate in Q4 2023 – Business Wire – Tris Pharma, ...
“Tris Pharma has a robust and expanding portfolio of clinically proven, best-in-class ADHD therapies,” said Englese. “I believe there is tremendous opportunity to help enhance the company’s commercial success by further expanding the availability of this growing portfolio, which offers a range of delivery and treatment options for both adults and children ...
Darolutamide, which is jointly developed by Bayer and Orion Corporation, is an oral androgen receptor inhibitor indicated for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease and for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC). Bayer will present the first ...
ByBayer AG
The MHLW submission is based on positive results from both the phase III PULSAR trial in nAMD and the phase II/III PHOTON trial in DME, in which aflibercept 8 mg met its primary endpoint, respectively. ...
ByBayer AG
If we are able to demonstrate a successful Phase III clinical trial, we believe Probudur may represent the first long acting local anesthetic with an opioid sparing label. ...
SMILE STUDY is a multi-institutional phase II clinical trial to determine the efficacy of an antiprogestin, Onapristone +fulvestrantas second line therapy for patients with HR+/HER2- metastatic breast cancer (MBC). ...
The study also provides evidence of a completely new mechanism of action that could usher in a new era of vascular medicine. 158 patients with narrowing of the carotid artery (carotid stenosis) took part in the clinical phase II study led by neurologist Professor Klaus Gröschel from the University Medical Centre Mainz. ...
The companies will jointly develop the compounds for the multiple system atrophy (MSA) and Parkinson’s disease (PD) indications based on early-stage clinical studies, and consider exploring additional indications based on clinical outcomes. ...
The Company expects the protocols for its clinical program to be influenced by the preclinical data and the Phase 1 clinical trial experience. ...
Funding from the Series B will allow Oligomerix to accelerate its transition into Phase 1 human clinical development planned for early 3Q 2022. Oligomerix closes Series B extension to accelerate transition into Phase 1 human clinical development. ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference and at ...
Lipella Pharmaceuticals Inc. said it saw positive top-line results from its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis. ...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MANIFEST-2 study – a global, randomized, double-blind clinical trial exploring pelabresib, an investigational BET inhibitor, in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis – are expected to be available in early ...
To request a meeting, please contact Cingulate Investor Relations at mkreps@darrowir.com. The Phase 3 clinical trial is an adult dose-optimization study to assess the onset and duration of efficacy along with the safety of CTx-1301 in adults with ADHD compared to placebo. ...